Inspire Investing LLC Acquires New Holdings in Bioventus Inc. $BVS

Inspire Investing LLC acquired a new position in Bioventus Inc. (NASDAQ:BVS) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 182,918 shares of the company’s stock, valued at approximately $1,670,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BVS. Caitong International Asset Management Co. Ltd increased its stake in Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after buying an additional 5,490 shares during the period. Prelude Capital Management LLC acquired a new stake in shares of Bioventus in the 3rd quarter worth approximately $74,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Bioventus in the third quarter valued at approximately $78,000. SG Americas Securities LLC bought a new position in shares of Bioventus in the fourth quarter valued at approximately $80,000. Finally, Brooklyn Investment Group acquired a new position in shares of Bioventus during the fourth quarter valued at approximately $91,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $9.44 on Wednesday. The stock’s fifty day simple moving average is $9.51 and its 200 day simple moving average is $8.78. The stock has a market capitalization of $788.62 million, a price-to-earnings ratio of 23.02, a PEG ratio of 1.26 and a beta of 0.67. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $11.25.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, sell-side analysts forecast that Bioventus Inc. will post 0.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barrington Research restated an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research report on Tuesday. CJS Securities began coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Tuesday, June 16th. Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Finally, Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $14.20.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.